Biolase (BIOL) Misses Q3 EPS by 47c

Biolase (NASDAQ: BIOL) reported Q3 EPS of ($1.10), $0.47 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $12.01 million versus the consensus estimate of $10.53 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Home Depot (HD) Tops Q2 EPS by 19c, reaffirms guidance
• Prenetics IM8 revenue jumps 359% in Q2, raises FY2026 guidance